Binosto® – The First and Only Buffered Solution for the Treatment of Osteoporosis
Binosto® (buffered alendronate sodium 70mg) is an effervescent tablet for oral solution that represents a true breakthrough in the treatment of osteoporosis – especially for those patients who prefer not to swallow tablets, or have difficulties swallowing pills. Taken just once a week, with a reduced volume of water to drink and no risk of a tablet getting lodged in the esophagus, Binosto® has the potential to improve long-term patient compliance and adherence to therapy, thereby decreasing the risk of disabling fractures.
Europe: Treatment of osteoporosis in postmenopausal women. Binosto® 70 mg reduces the risk of vertebral and hip fractures.
United States: Treatment of osteoporosis in postmenopausal women. Binosto® increases bone mass and reduces the incidence of fractures, including those of the hip and spine. Binosto® is indicated for treatment to increase bone mass in men with osteoporosis.
Binosto® is licensed in 50+ countries, commercialized in 18 countries and expected to expand to additional counties in 2019. EffRx is currently looking for Partners to commercialize Binosto® in selected European countries, Latin America and the Asia-Pacific.
Please visit www.binosto.co.uk for the EU approved prescribing information.
For Business Development inquiries please contact: email@example.com.
Information for Healthcare professionals only. Please refer to the official prescribing information and approved indications, contraindications, and warnings in your country.